- Home
- MOBX vs ALGS Comparison
MOBX vs ALGS Comparison
Compare MOBX & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- ALGS
- Stock Information
- Founded
- MOBX 2020
- ALGS 2018
- Country
- MOBX United States
- ALGS United States
- Employees
- MOBX N/A
- ALGS 70
- Industry
- MOBX
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- MOBX
- ALGS Health Care
- Exchange
- MOBX Nasdaq
- ALGS Nasdaq
- Market Cap
- MOBX 31.4M
- ALGS 27.9M
- IPO Year
- MOBX N/A
- ALGS 2020
- Fundamental
- Price
- MOBX $0.71
- ALGS $5.66
- Analyst Decision
- MOBX
- ALGS Strong Buy
- Analyst Count
- MOBX 0
- ALGS 1
- Target Price
- MOBX N/A
- ALGS $70.00
- AVG Volume (30 Days)
- MOBX 144.4K
- ALGS 184.5K
- Earning Date
- MOBX 05-13-2025
- ALGS 05-06-2025
- Dividend Yield
- MOBX N/A
- ALGS N/A
- EPS Growth
- MOBX N/A
- ALGS N/A
- EPS
- MOBX N/A
- ALGS N/A
- Revenue
- MOBX $9,326,000.00
- ALGS $3,945,000.00
- Revenue This Year
- MOBX N/A
- ALGS $580.86
- Revenue Next Year
- MOBX N/A
- ALGS N/A
- P/E Ratio
- MOBX N/A
- ALGS N/A
- Revenue Growth
- MOBX 1023.61
- ALGS N/A
- 52 Week Low
- MOBX $0.55
- ALGS $3.76
- 52 Week High
- MOBX $3.62
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- MOBX 35.34
- ALGS 34.64
- Support Level
- MOBX $0.70
- ALGS $4.33
- Resistance Level
- MOBX $0.85
- ALGS $5.94
- Average True Range (ATR)
- MOBX 0.08
- ALGS 0.76
- MACD
- MOBX 0.00
- ALGS 0.47
- Stochastic Oscillator
- MOBX 11.23
- ALGS 71.58
About MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.